Intellipharmaceutics International Inc (IPCI) 4.21

New Post Public Reply Private Reply Replies (0) Message Board

Apr 9, 2014 at 7:51 PM

Intellipharmaceutics International Inc (IPCI) 4.21 $IPCI

Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. was a big mover last session, as its shares rose nearly 9% on the day.

Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:

IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.

Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue?

4 Stocks Under to Trade for Breakouts
at The Street - Fri Mar 21, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.

Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting&quot

.

Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.

Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.

Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.

5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.

Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.

Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.

Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.

Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
GlobeNewswire - Mon Feb 03, 6:00AM CST
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales

5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.

Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics
PR Newswire - Mon Dec 02, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Mon Dec 02, 6:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Financial Officer, will present a Company overview at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York at 1:00pm EST on Wednesday, December 4, 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigate360 Data Breach Concerns: Legal Insights

No Safety in a Storm: Navigate360's Data Breach Fiasco When you think of data breaches, you often envision some shady hacker in a hoodie, but here we are with Navigate360 losing control of a massive chunk of sensitive data involving school safety tips. You'd hope companies with serious access to personal information are better at keeping secrets, right? Yet, here we are,...

Hollywood Vampires' Limited Art Sparks Las Vegas Buzz

A Collaboration to Captivate Art and Rock Enthusiasts When it comes to mixing rock and roll with fine art, Markus Klinko's exclusive photograph featuring the Hollywood Vampires hits the nail on the head. It’s not just an image; it’s a slice of modern rock history immortalized on paper. This new release, a portrait capturing the raw passion of Alice Cooper, Johnny...

MetroScape: Local Roots Fuel Bold DFW Growth Plans

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...

Caesarstone Loses $67.7M Case Over Artificial Stone Risks

A Demand for Accountability in the Courts A Los Angeles jury recently handed down a whopping $67.7 million verdict against Caesarstone Ltd. and its U.S. operations, marking a win for Dennys Rene Rivas Williams and his family. No sugarcoating here—this is a landmark case for artificial stone fabricators suffering from silicosis. The jury found Caesarstone entities a...

First Responders Honored in Times Square Hero Ceremony

Stepping up to Spotlight Courage In a world that often seems to teeter on chaos, it's those unsung heroes—the first responders—who stand ready to turn panic into repose. October 28th saw Times Square in New York City transform into a beacon of appreciation as the First Responders Children's Foundation (FRCF) applauded nineteen fearless foes of danger. Picture that...

Unmasking Hidden Mold: Early Signs and Triggers

Mold Behind Walls: The Silent Menace Who knew that a pesky odor could hint at a whole underground world of issues? Hidden mold behind walls isn't just an ugly visitor—it's got a PhD in causing headaches. Haynes outta Little Rock is cluing us in, and we’d better listen up if we want to nip this menace in the bud. Sniff It Out You walk into a room, and there it is—an...

Samuel Oschin Air & Space Center Takes Flight This Fall

The Grand Unveiling: November Highlights Look at this: space nerds, dreamers, and just about anybody with a heartbeat and a sense of wonder should circle November 13, 2026, like a kid with a candy store gift card. That's when the California Science Center throws open the doors to the Samuel Oschin Air and Space Center. You might as well slap a 'world's first' sticker on...

Travelers Juggle Cash and Cards Abroad: Survey Insights

Travel Spending: Balancing Convenience with Costs Navigating the financial landscape when you're a traveler abroad ain't always a walk in the park, folks. A fresh survey by Upgraded Points takes a gritty dive into how 1,500 globe-trotters juggle cash and cards while hopping across borders. The nitty-gritty? Messy exchange rates, sneaky fees, and the dreaded declined...

Unity Crucial for Global South's Economic Gains

Anytime you hear the 'Global South' being bandied about these days, you know someone's talking about the clout shifting in the world. In Beijing this week, they were hashing out how these nations can crank up their collective volume on the global stage. Gathering Brains in Beijing At the Global Strategic Dialogue 2026, held slap-bang in Beijing, experts and high-profile...

Motiva's Q3 2026 Results: Strategic Moves Drive Growth

Strategic Transactions and Financial Highlights Motiva's third quarter of 2026 shows a company not just coasting but recalibrating its trajectory. Big moves had ripple effects on their financial landscape, most notably their sale of the Airport Platform, concluded for a hefty R$5.2 billion. Their portfolio's trimming isn't just a garage sale but a thought-out step...